Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection After Kidney Transplantation

References

• Kim SI. Bacterial infection after liver transplantation. World J Gastroenterol. 2014;20(20):6211–6220. doi:10.3748/wjg.v20.i20.621124876741
   PubMed Web of Science ®Google Scholar
• Aguado JM, Silva JT, Fernandez-Ruiz M, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev. 2018;32(1):36–57. doi:10.1016/j.trre.2017.07.001
   Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-328356109
   PubMed Web of Science ®Google Scholar
• Pouch SM, Kubin CJ, Satlin MJ, et al. Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients. Transpl Infect Dis. 2015;17(6):800–809. doi:10.1111/tid.1245026341757
   PubMed Web of Science ®Google Scholar
• Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15–21. doi:10.1177/204993611562170926862399
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37(5):415–419. doi:10.1016/j.ijantimicag.2011.01.01221429716
   PubMed Web of Science ®Google Scholar
• Chiu SK, Wu TL, Chuang YC, et al. National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS One. 2013;8(7):e69428. doi:10.1371/journal.pone.006942823894478
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. The “Old” and the “New” antibiotics for MDR Gram-negative pathogens: for whom, when, and how. Front Public Health. 2019;7:151. doi:10.3389/fpubh.2019.0015131245348
   PubMed Web of Science ®Google Scholar
• Das S, Li J, Riccobene TJ, Carrothers TJ, Newell P. Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. Antimicrob Agents Chemother. 2019;63(4):e02187–18. doi:10.1128/AAC.02187-1830670413
   PubMed Web of Science ®Google Scholar
• Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–S575. doi:10.1093/cid/ciz83031724043
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(2):159–177. doi:10.1007/s40265-013-0013-723371303
   PubMed Web of Science ®Google Scholar
• Gu J, Xu J, Zuo TT, Chen YB. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: ceftazidime-avibactam against CR-KP infections. J Glob Antimicrob Resist. 2021;26:20–25. doi:10.1016/j.jgar.2021.04.02234020072
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883–17. doi:10.1128/AAC.00883-1728559250
   PubMed Web of Science ®Google Scholar
• LeGall JR, Loirat P, Alpcrovitch A. APACHE II_ a severity of disease classification system. Crit Care Med. 1986;14(8):754–755. doi:10.1097/00003246-198608000-00027
   PubMed Web of Science ®Google Scholar
• Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22(7):707–710. doi:10.1007/BF17097518844239
   PubMed Web of Science ®Google Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi:10.1016/j.ajic.2008.03.00218538699
   PubMed Web of Science ®Google Scholar
• Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017;61(2):Feb. doi:10.1128/AAC.01964-16
   Web of Science ®Google Scholar
• Rodriguez-Nunez O, Ripa M, Morata L, et al. Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2018;15:136–139. doi:10.1016/j.jgar.2018.07.01030036695
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. M100-S28. Performance standards for antimicrobial susceptibility testing: 28th informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618. doi:10.1093/cid/ciw63627624958
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364. doi:10.1093/cid/ciy492/503521729893802
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase–producing K. pneumoniae infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73(9):1664–1676. doi:10.1093/cid/ciab17633618353
   PubMed Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171. doi:10.1093/cid/cix78329020404
   PubMed Web of Science ®Google Scholar
• Tsolaki V, Mantzarlis K, Mpakalis A, et al. Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients. Antimicrob Agents Chemother. 2020;64(3). doi:10.1128/AAC.02320-19
   PubMed Web of Science ®Google Scholar
• Falcone M, Bassetti M, Tiseo G, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24(1):29. doi:10.1186/s13054-020-2742-932000834
   PubMed Web of Science ®Google Scholar
• Zheng G, Zhang J, Wang B, et al. Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Ther. 2021;10(3):1699–1713. doi:10.1007/s40121-021-00479-734241831
   PubMed Web of Science ®Google Scholar
• Gottig S, Frank D, Mungo E, et al. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. J Antimicrob Chemother. 2019;74(11):3211–3216. doi:10.1093/jac/dkz33031365094
   PubMed Web of Science ®Google Scholar
• Fiore M, Alfieri A, Di Franco S, et al. Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis. Antibiotics. 2020;9(7):388. doi:10.3390/antibiotics9070388
   Web of Science ®Google Scholar
• Caston JJ, Gallo M, Garcia M, et al. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort. Int J Antimicrob Agents. 2020;56(3):106075. doi:10.1016/j.ijantimicag.2020.10607532629116
   PubMed Web of Science ®Google Scholar
• Zhang P, Shi Q, Hu H, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect. 2020;26(1):124e1–124e4. doi:10.1016/j.cmi.2019.08.02031494252
   PubMed Web of Science ®Google Scholar
• Li D, Liao W, Huang HH, et al. Emergence of hypervirulent ceftazidime/avibactam-resistant Klebsiella pneumoniae isolates in a Chinese tertiary hospital. Infect Drug Resist. 2020;13:2673–2680. doi:10.2147/IDR.S25747732821131
   PubMed Web of Science ®Google Scholar